With a market capitalization (market cap) of $6.94B — a measure of how much the company is worth — Immunovant, Inc. ranks #1,129 among the 2,510 companies tracked, and 133rd in Healthcare as of October 2, 2026. Shares trade at $33.62, down 0.09% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 2, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $6.91B | +33.45% | $33.62 |
| 2025 | Dec 31, 2025 | $5.18B | +37.92% | $25.42 |
| 2024 | Dec 31, 2024 | $3.75B | -38.34% | $24.77 |
| 2023 | Dec 29, 2023 | $6.09B | +166.79% | $42.13 |
| 2022 |
Ranking figure $6.94B as of October 2, 2026.
Immunovant, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $33.62 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $6.91B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2026) used a weighted-average 182,421,233 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2026 weighted-average shares would give about $6.13B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2026
FY 2026
Undefined when revenue is zero
FY 2026
Undefined when revenue is zero
FY 2026
FY 2026
FY 2026
FY 2026
Not in this snapshot
FY 2026 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2026.
Visit websiteAs of October 2, 2026, Immunovant, Inc. (IMVT) is worth $6.94B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2026, Immunovant, Inc.’s book equity is about $852.59M. Market cap is the market value of the outstanding shares. As of October 2, 2026, its market cap is $6.94B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Immunovant, Inc. ranks #1,129 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #133 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| Dec 30, 2022 |
| $2.28B |
| +130.25% |
| $17.75 |
| 2021 | Dec 31, 2021 | $991.2M | — | $8.52 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2026
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1126 | Fluor Corporation FLR | $6.97B | +1.16% |
| #1127 | Norwegian Cruise Line Holdings Ltd. NCLH | $6.95B | +3.45% |
| #1128 | STAG Industrial, Inc. STAG | $6.95B | +0.92% |
| #1130 | B2Gold Corp. BTG | $6.93B | +0.58% |
| #1131 | AXIS Capital Holdings Limited AXS | $6.92B | -0.66% |
| #1132 | Urban Outfitters, Inc. URBN | $6.92B | +2.58% |
Immunovant, Inc.’s ranking market cap of $6.94B comes from the same snapshot as the rest of this site, as of October 2, 2026. It is not share price multiplied by the FY 2026 weighted-average share count of 182,421,233. The historical market-cap series last observed $6.91B on October 2, 2026.
Over the past year, Immunovant, Inc.’s market cap is up 127.56%, using historical market-cap records rather than today’s share count applied to past prices.
Immunovant, Inc. (IMVT) shares trade at $33.62, down 0.09% on the day, as of October 2, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.